View on market: Volatility Prevails, Market is searching for better value
Asian indices opened higher with Japan indices rising the most following the election outcome. On Friday, all three major Wall Street indices opened higher, as investors aimed to finish a week of volatility on a positive note. In contrast, Indian benchmark equity indices fell for the fourth week in a row, marking their longest losing streak since the five-week period ending earlier this year. On a daily basis, these indices declined for the fifth consecutive session. Overseas investors continued to sell Indian equities, marking the 20th straight session of net selling. However, domestic institutional investors remained active buyers, maintaining a streak of 24 consecutive sessions of net buying. This divergence highlights contrasting sentiments in the Indian market, with foreign investors pulling back while local institutions continue to support equities. Overall, the market is experiencing significant fluctuations as various factors influence investor behavior.
Economic Calendar:
- USD: House Price Index (YoY) (Aug) on 29th October 2024.
- IND: Bank Loan Growth Rate on 1st November 2024.
- USD: Mortgage Market Index on 30th October 2024.
- IND: RBI Monetary and Credit Information Review on 31st October 2024.
IPO Watch:
Company | Open | Close | Price | View |
Afcons Infrastructure Ltd | 25-Oct | 29-Oct | 440-463 | Apply |
Brokerage Radar:
UBS ON HPCL:
Maintain Buy with target price of Rs 445, All-round focus on investments to support growth and profitability over time, Strong integrated margins offset by under-recoveries and inventory, Improving physical performance with key projects reaching/ near completion.
INVESTEC ON ICICI BANK:
Maintain Buy; Hike target price to Rs 1450 from Rs 1350, Outperforming peers on all counts, Positive surprise on credit costs leads to RoA beat, Credit/deposits growth continues to remain strong, NIMs decline on higher incremental cost of funds.
HSBC ON SHRIRAM FINANCE:
Maintain Buy; Hike target price to Rs 3725 from Rs 3600, Q2 performance reinforced our view that Shriram is in its most convincing operating period since 2010, Delivery on all parameters was strong, guidance was re-iterated and there were no misses in asset quality or growth, Hike target to reflect strengthening competitiveness.
NUVAMA ON IDFC FIRST BANK:
Maintain Hold, Cut target price to Rs 60 vs Rs 72, Management raised the full-year credit cost guidance to 2.25% from 1.85%, PAT slid 77% YoY/74% QoQ due to a spike in credit cost to 3.15% from 1.9% QoQ, MFI asset quality deteriorated, SMA in other segments-including PL and CC-is tracking better than industry, Strong loan-deposit growth, lower opex and higher trading gains.
International Markets:
U.S & Europe:
Particulars | 25th Oct | Chg. | Chg.(%) |
Nasdaq | 18,518.61 | 103.12 | 0.56 |
Dow | 42,114.40 | -259.96 | -0.61 |
FTSE | 8,248.84 | -20.54 | -0.25 |
CAC | 7,497.54 | -5.74 | -0.08 |
DAX | 19,463.59 | 20.59 | 0.11 |
Dow Fut.* | 42,500 | 179 | 0.42 |
*As per 28th October.
Asian markets:
Particulars | 28th Oct | Chg. | Chg.(%) |
GIFT Nifty | 24,244 | 51.25 | 0.23 |
Nikkei | 38,485.67 | 571.75 | 1.51 |
Straits Times | 3,596.60 | 3.19 | 0.09 |
Hang Seng | 20,629.66 | 39.51 | 0.19 |
Shanghai | 3,308.00 | 8.30 | 0.25 |
Stocks strong on Chart:
Index | F&O | Cash |
HDFC BANK | COFORGE | MAX ESTATE |
AXIS BANK | TATA POWER | JIO FINANCE |
TCS | ICPA LAB | JK LAKSHMI |
ICICI BANK | INDIAN HOTEL | BAYER CROP |
INFOSYS | BLUE STAR | |
SUNPHARMA | CEAT |
Commodities & Currency:
Particulars | Current Price | Chg.(%) |
USD/INR | 84.082 | -0.02 |
Brent | 72.34 | -4.35 |
Gold | 78,577 | 0.06 |
Silver | 97,269 | 0.24 |
FIIs & DIIs:
Particulars | 25th Oct | 24th Oct |
FIIs | -3,036.75 | -5,062.45 |
DIIs | 4,159.29 | 3,620.47 |
News Update:
Company
Bandhan Bank: | The board approved the appointment of Partha Pratim Sengupta as managing director and chief executive officer for three years effective Nov. 1. |
Power Mech Projects: | The company incorporated step- down unit PMTS Tech In Dubai for software development and tech services. |
Aurobindo Pharma: | The company completed the acquisition GLS Pharma for Rs 22.5 crore. |
Suven Pharmaceuticals: | NCLT approved merger of arm Casper Pharma with the company. |
Source: Moneycontrol, Bloomberg Quint, Investing Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)Disclosure AppendixAnalyst Certification (For Reports)Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.comThe analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.Research ExcerptsThis note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.Company-Specific DisclosuresImportant disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.Options related research:If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.inOther DisclosuresAll research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.Ownership and material conflicts of interest DisclosureElite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.Country Specific DisclosuresIndia – For private circulation only, not for sale.Legal Entities DisclosuresMr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.inEWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
- Reports
- a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
- Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWLProvided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.